 Based on these results, the primary goal of MEMORI study is to evaluate the R0 resection rate for patients with metabolically ie, according to PET criteria chemotherapy-resistant locally advanced AEG, who receive an intensified neoadjuvant chemoradiotherapy INRCT. Secondary it is planned to investigate molecular and metabolic biomarkers in relation to their predictive and prognostic value by correlating them with histopathologic responses and clinical outcome in an exploratory approach. 